Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulse Biosciences Inc PLSE

Healthcare Medical Devices
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it... see more

Recent & Breaking News (NDAQ:PLSE)

Pulse Biosciences Grants Equity Incentive Awards to New Employees

Business Wire October 15, 2018

Pulse Biosciences Announces Continued Expansion of Its Clinical Study Programs in Dermatology

Business Wire October 11, 2018

Pulse Biosciences to Present at the Cantor Global Healthcare Conference

Business Wire October 1, 2018

Pulse Biosciences Grants Equity Incentive Awards to New Employees

Business Wire September 19, 2018

Robbins Arroyo LLP Is Investigating the Officers and Directors of Pulse Biosciences, Inc. (PLSE) on Behalf of Shareholders

Business Wire August 13, 2018

Pulse Biosciences Grants Equity Incentive Awards to New Employees

Business Wire August 3, 2018

Pulse Biosciences Quarterly Investor Conference Call

Business Wire July 31, 2018

Pulse Biosciences Treats Initial Patient in Its Human Study Evaluating the Effects of Nano-Pulse Stimulation in Basal Cell Carcinoma

Business Wire July 30, 2018

Pulse Biosciences to Report Second Quarter 2018 Financial Results and Operational Highlights

Business Wire July 12, 2018

Pulse Biosciences Announces Treatment of First Patients in Study to Evaluate the Safety and Efficacy of Novel Nano-Pulse Stimulation for the Treatment of Sebaceous Hyperplasia Lesions

Business Wire July 10, 2018

Robbins Arroyo LLP Is Investigating the Officers and Directors of Pulse Biosciences, Inc. (PLSE) on Behalf of Shareholders

Business Wire June 25, 2018

Pulse Biosciences Grants Equity Incentive Awards to New Employees

Business Wire June 25, 2018

Kaskela Law LLC Announces Investigation of Pulse Biosciences, Inc. on Behalf of Stockholders

Accesswire June 20, 2018

Pulse Biosciences Grants Equity Incentive Awards to New Employees

Business Wire May 16, 2018

Pulse Biosciences Quarterly Investor Conference Call

Business Wire May 8, 2018

Pulse Biosciences to Report First Quarter 2018 Financial Results and Operational Highlights

Business Wire April 30, 2018

Pulse Biosciences Grants Equity Incentive Awards to New Employee

Business Wire April 18, 2018

Mid-Day Market Update: SemiLEDs Falls Following Q2 Results; Pulse Biosciences Shares Surge

Benzinga.com  April 13, 2018

Mid-Morning Market Update: Markets Mostly Flat; Citigroup Earnings Beat Expectations

Benzinga.com  April 13, 2018

Pulse Biosciences Announces Positive Results from Its First Study Evaluating a Clinical Target at Major Scientific Meeting

Business Wire April 12, 2018